Nucleus Network
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Australia · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Clive Berghofer Cancer Research Centre C...Phone Number
+61 737072720Website
www.nucleusnetwork.comRevenue
$16 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
3
1
1
About Nucleus Network
Nucleus Network is a company that operates in the Biotechnology industry. It employs 101-250 people and has $10M-$25M of revenue. The company is headquartered in Melbourne, Victoria, Australia.Explore more
Nucleus Network Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nucleus Network your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Nucleus Network launches new products
Check if Nucleus Network has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Nucleus Network has new funding data
Earning: See what the market has to say on Nucleus Network recently announced quarterly report
Click to see if Nucleus Network had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Nucleus Network is spiking on competitors!
Nucleus Network, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Nucleus Network
Recommended Actions
Reach out to Masked Content who joined Nucleus Network as Masked Content
Find more new buyers
Compare Similar Companies to Nucleus Network
Compare insights from companies similar to Nucleus Network, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nucleus Network is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Nucleus Network is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Nucleus Network.
Nucleus Network Tech Stack
A closer look at the technologies used by Nucleus Network
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Person-Based
Promotion
Executive Move
Executive Moves, Promotion
Hiring Plans
Nucleus Network has more open roles in Clinical Operations than it has had at any time in the past 12 months.
Open Position
Nucleus Network News & Media
Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
Las Vegas, NV, July 12, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For SAD, the drug was safe and well tolerated. Concussions repOdyssey Health, Inc. Completes Safety Evaluation of Cohort II for Concussion Drug
Las Vegas, NV, June 29, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort II of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Data from Cohort II indicates that the drug was safe and well-tolerated.Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
Irvine, CA, May 05, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV-002, in their Phase I clinical trial. Odyssey’s trial is administering PRV-002, their novel drug to treat concussion, to healthy human subjects. Thus far the drug has shown to be safe and well tolerated. EachNucleus Network opens satellite outpatient clinic in Geelong
Australia’s largest Phase 1 clinical trials provider, Nucleus Network, announces satellite outpatient clinic set to open this September in Geelong, Victoria. GEELONG, VICTORIA, MELBOURNE, July 28, 2021 /EINPresswire.com/ -- Australia’s largest Phase 1 …
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Nucleus Network
Sign Up For FreeTo access detailed company insights
Nucleus Network is a company that operates in the Biotechnology industry. It employs 101-250 people and has $10M-$25M of revenue. The company is headquartered in Melbourne, Victoria, Australia.... Read More
